🔗 Share this article

As America continues making sweeping adjustments to its vaccination guidelines, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by questioning COVID-19 vaccinations during the pandemic and has focused upon possible deaths after Covid immunization in her recent tenure at the FDA.

Proposed Changes to Pediatric Vaccine Schedule

Health officials planned to unveil radical changes to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, according to reports – a significant shift that would put the US out of alignment with a large portion of the international standard with no evidence for benefit. The announcement has been postponed until the new year.

In place of Vinay Prasad, Dr. Høeg is listed to speak at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Høeg has often pushed for ending certain pediatric vaccine recommendations in the US to become more in line with Denmark's approach, a society with nationalized medicine and a citizenry about the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – traditionally the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Qualifications

The appointee has no obvious experience in pharmaceutical research, approval processes or administrative roles, which has been standard for previous leaders of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in managing a sizeable institution. She is not an expert in industry regulation.”

Past commissioners of CBER would “understand legal statutes and the research of medication creation”, said Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who ran CBER have had.”

This division has an immense workload at the FDA, she stated.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office approves numerous generic drugs. There’s a biosimilars division, non-prescription drug unit and so forth, and each of these need to be supervised,” she said. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a major administrative element to the position, which supervises more than 5,000 employees. “It’s a huge management job, if you perform it correctly,” the former official concluded.

Agency Reaction and Disputed Policies

In response to concerns about Høeg’s qualifications and whether this selection represents increased cooperation among regulatory chiefs on immunizations, a press secretary stated that the “questions rely on inaccurate premises”.

“This background aligns with the functions of her role,” the official explained, citing the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a disputed one-day drug-approval program that reportedly concerned her predecessors. “By what process are these drugs being selected for this fast-track system? Who is making the calls?” Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards less stringent oversight of pharmaceuticals, with the exception of shots.”

Documented Past Work on Immunizations

With immunizations, Høeg has a more established, if concerning, history, critics said. She authored a study using unconfirmed crowd-sourced reports to assess the rate of myocarditis after COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the incoming government included revising rules for recently developed shots and discontinuing “non-essential” immunizations, she remarked following the vote on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of excluding adolescent males from getting COVID-19 vaccinations.

“She’s an complete ideologue who begins with her beliefs and reverse-engineers to accommodate the data in a very disingenuous, fraudulent way,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|